Answers to 5 Common Questions about Acute Exacerbations of COPD

References

• . Donaldson GC, Wedzicha JA. COPD exacerbations. 1: Epidemiology. Thorax. 2006;61(2):164–168
   PubMed Web of Science ®Google Scholar
• . Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl. 2003;41:46s–53s
   PubMedGoogle Scholar
• . Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925–931
   PubMed Web of Science ®Google Scholar
• . Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161(5):1608–1613
   PubMed Web of Science ®Google Scholar
• . Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 pt 1):1418–1422
   PubMed Web of Science ®Google Scholar
• . Spencer S, Jones PW; GLOBE Study Group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax. 2003;58(7):589–593
   PubMed Web of Science ®Google Scholar
• . Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117(5 suppl 2):398S–401S
   PubMed Web of Science ®Google Scholar
• . Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of COPD. Updated November 2008. www.goldcopd.com
   Google Scholar
• . Miravitlles M, Mayordomo C, Artes M, Sanchez-Agudo L, Nicolau F, Segii JL. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Estudio Observacional de la Limitacion Obstructiva al Flujo aEreo. Respir Med. 1999;93(3):173–179
   PubMed Web of Science ®Google Scholar
• . Bach PB, Brown C, Gelfand SE, McCrory DC; American College of Physicians-American Society of Internal Medicine; American College of Chest Physicians. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med. 2001;134(7):600–620
   PubMed Web of Science ®Google Scholar
• . McCrory DC, Brown CD. Anti-cholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;(4):CD003900
   Google Scholar
• . Wood-Baker RR, Gibson PG, Hannay M, Walters EH, Walters JA. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2004;(1):CD001288
   Google Scholar
• . Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, Garcia-Aymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;(2):CD004403
   Google Scholar
• . Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 2000;117(6):1638–1645
   PubMed Web of Science ®Google Scholar
• . Martinez FJ. Acute bronchitis: state of the art diagnosis and therapy. Compr Ther. 2004;30(1):55–69
   PubMedGoogle Scholar
• . Martinez FJ, Han MK, Flaherty K, Curtis J. Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Expert Rev Anti Infect Ther. 2006;4(1):101–124
   PubMedGoogle Scholar
• . Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58(5):399–404
   PubMed Web of Science ®Google Scholar
• . Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow limitation in patients with COPD. Eur Respir J. 2006;27(3):547–555
   PubMed Web of Science ®Google Scholar
• . Calverley PM, Anderson JA, Celli B, .; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789
   PubMed Web of Science ®Google Scholar
• . Aaron SD, Vandemheen KL, Fergusson D, .; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasonesalmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146(8):545–555
   PubMed Web of Science ®Google Scholar
• . Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(RR–8);1–24
   Google Scholar
• . Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med. 1999;159(20):2437–2442
   PubMedGoogle Scholar
• . Garcia-Aymerich J, Barreiro E, Farrero E, Marrades RM, Morera J, Antó JM. Patients hospitalized for COPD have a high prevalence of modifiable risk factors for exacerbation (EFRAM study). Eur Respir J. 2000;16(6):1037–1042
   PubMed Web of Science ®Google Scholar
• . Garcia-Aymerich J, Farrero E, Félez MA, Izquierdo J, Marrades RM, Antó JM; Estudi del Factors de Risc d'Agudització de la MPOC investigators. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax. 2003;58(2):100–105
   PubMed Web of Science ®Google Scholar